When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
NVS - FDA OKs Novartis' Tabrecta for certain lung cancer patients
Novartis AG
Incyte (INCY-1.9%) announces that the FDA has approved exclusive licensee Novartis' (NVS+1.2%) Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. The nod applies to a first-line setting as well as previously treated patients regardless of prior treatment type.
More news on: Incyte Corporation, Novartis AG, Healthcare stocks news,